SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (154)9/27/1999 2:32:00 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 395
 
From the Acknowledgements of Storb et al: ... We thank Dr Peter Linsley, formerly of Bristol Myers Squibb Research, Seattle, WA, and now Rosetta Inphamatics, Kirkland, WA, for the gift of CTLA4IG; Dr Wen Chyi Shyu, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, for measuring CTLA4Ig serum levels ...

What's the IP situation here? Anyone knows?

PB



To: scaram(o)uche who wrote (154)10/7/1999 10:03:00 AM
From: Manfred Sondermann  Read Replies (1) | Respond to of 395
 
Richard, referring to the Forbes article mentioned in #147,
can you please put some light to those of us who are no
physicians. What is the difference between CTLA4-Ig of RGEN
and its competition products of Abgenics and BioTransplant.
What about their efficacies?

Thanks, Manfred


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News